Arvind Dasari, MD, MS, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of updates in fruquintinib, a novel VEGF inhibitor, in patients with metastatic colorectal cancer. Findings from the FRESCO (NCT02314819) and FRESCO-2 (NCT04322539) trials, which assessed fruquintinib in heavily pretreated patients, demonstrated promising efficacy and a quality of life analyses further showed patients receiving the investigational drug being well tolerated. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ